The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study Carl-Jacob Holmberg , Lars Ny , Tina J Hieken , Matthew S Block , Michael J Carr , Vernon K Sondak , Christoffer Örtenwall , Dimitrios Katsarelias , Florentia Dimitriou , Alexander M Menzies , Robyn Pm Saw , Aljosja Rogiers , Richard J Straker , Giorgos Karakousis , Rona Applewaite , Lalit Pallan , Dale Han , John T Vetto , David E Gyorki , Emilia Nan Tie , Maria Grazia Vitale , Paulo A Ascierto , Reinhard Dummer , Jade Cohen , Jane Yc Hui , Jacob Schachter , Nethanel Asher , H Helgadottir , Harvey Chai , Hidde Kroon , Brendon Coventry , Luke D Rothermel , James Sun , Matteo S Carlino , Zoey Duncan , Kristy Broman , Jeffrey Weber , Ann Y Lee , Russell S Berman , Jüri Teras , David W Ollila , Georgina V Long , Jonathan S Zager , Alexander van Akkooi , Roger Olofsson Bagge European Journal of Cancer（2022）
摘要
•The efficacy of immunotherapy for melanoma in-transit metastases is unknown.•An international multicenter retrospective cohort study.•Systemic immunotherapy is an effective treatment for melanoma in-transit metastases.
更多 查看译文
关键词
Melanoma, In-transit metastasis, Immune checkpoint inhibitor, PD-1, Nivolumab, Pembrolizumab, Ipilimumab
AI 理解论文
溯源树
样例
